Opus Genetics (NASDAQ:IRD – Get Free Report) posted its earnings results on Monday. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.93), Zacks reports. The firm had revenue of $3.40 million during the quarter, compared to analyst estimates of $11.10 million. Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%.
Opus Genetics Trading Down 2.8 %
Shares of IRD opened at $0.98 on Tuesday. The company’s 50 day moving average price is $1.08. The firm has a market capitalization of $31.46 million, a P/E ratio of -0.90 and a beta of 0.28. Opus Genetics has a one year low of $0.81 and a one year high of $1.56.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Opus Genetics in a report on Wednesday, February 19th.
Opus Genetics Company Profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
See Also
- Five stocks we like better than Opus Genetics
- Election Stocks: How Elections Affect the Stock Market
- CAVA Group Stock: Time to Take the Dip on This Investment Trip?
- How to Use Stock Screeners to Find Stocks
- From Trading to Checking Accounts: Robinhood’s Big Bet on Banking
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 5 Hot Stock Buys for Investors in April
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
